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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
Main objectives
• To determine the effectiveness of theory-based and non-theory based health psychology interventions for improving adherence
to maintenance therapy in adults with asthma
Secondary objectives
• To compare the effectiveness of adherence interventions which are based on theory, as defined by the Theory Coding Scheme
(TCS), to interventions which are not theory-based
• To identify and describe, using the TSC and Theoretical Domain Framework (TDF), the different health psychology theories
which have been used in interventions to improve adherence to maintenance therapy in adults with asthma
• To evaluate the extent to which health psychology theory has been applied to the development of adherence interventions in
asthma
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B A C K G R O U N D
Description of the condition
Asthma is a long-term inflammatory condition of the airways
which results in variable symptoms and affects more than 300 mil-
lion adults and children worldwide, with marked ethnic and racial
variations in prevalence (Global Asthma Report 2014; Gorman
2009; Netuveli 2005). In the UK, it is estimated that nearly 30%
of people will report symptoms suggestive of asthma at some point
during their lives, which amounts to over 18 million individuals
(Mukherjee 2016). The prevalence of asthma is likely still increas-
ing across both high and lower income countries. The reason for
the increasing prevalence is not fully understood, but is thought
to be largely due to environmental factors (Global Asthma Report
2014).There has been a recent decline in healthcare utilisation in
some settings, which may be a result of improved care (Anandan
2010; Asher 2006; Braman 2006). Asthma can cause shortness
of breath, chest tightness and cough, and typically presents with
wheezing.Many peoplewith asthma experience intermittentwors-
ening of their asthma symptoms, known as ’exacerbations’, ’flare-
ups’ or ’attacks’ (GINA 2016). Approximately 20% of people with
asthma have at some point been admitted to hospital or have at-
tended an emergency department for asthma treatment (Rodrigo
2004). Attacks can be triggered by common irritants and allergens
such as pollution, tobacco smoke, pollen and house dust mites,
as well as upper respiratory tract infections (CDC 2016). Most
asthma-related deaths occur in middle-income and low-income
countries. Poorly controlled asthma places a huge burden on in-
dividuals, their families and society (WHO 2013), a burden that
has been increasing over the last 40 years (Braman 2006)
The mainstay of asthma treatment for most people with asthma
is inhaled corticosteroids (ICS) (BTS/SIGN 2016; NICE 2017).
ICS are also known as ’preventer’ or ’controller’ medications, and
are used once or twice daily (depending on the preparation), even
when the patient feels well, to treat inflammation and maintain
control over asthma symptoms. In addition, people with asthma
are prescribed short-acting beta-agonists (SABAs), often known as
’reliever’ medications, to give short-term relief from acute worsen-
ing of symptoms (BTS/SIGN 2016; NICE 2017). Of note, inap-
propriate SABA use may be associated with increased morbidity
and healthcare costs (FitzGerald 2017). Both types of drug are
usually delivered directly to the patient’s airways via an inhaler.
ICS work by suppressing the multiple inflammatory cascades that
are activated in the airways of a person with asthma. Inflammation
leads to increased inflammatory swelling of the lining of the air-
ways, mucus production and airway constriction, which cause the
variable symptoms of asthma. Reduction in underlying inflamma-
tion through sustained use of ICS can result in symptom improve-
ment and reduced asthma-relatedmorbidity andmortality (Barnes
2003; Bårnes 2015). Commonly used ICS include budesonide,
beclomethasone, fluticasone (propionate and furoate), mometa-
sone and ciclesonide. These can be given alone or in combina-
tion with other controller medications such as inhaled long-acting
beta2-agonists (LABAs) or inhaled long-acting muscarinic antago-
nists (LAMAs); oral drugs such as leukotriene receptor antagonists
(LTRAs) or theophylline; or injectable drugs such as omalizumab
or mepolizumab (BNF; BTS/SIGN 2016; NICE 2017).
Despite the effectiveness of treatment with ICS for maintaining
asthma control, many patients do not take ICS as prescribed, and
are considered to have poor “adherence” to their treatment (Bårnes
2015), with average ICS adherence rates ranging from 30% to
70% (Gamble 2009; Morton 2014). In asthma, an adherence rate
of at least 80% to ICS is associated with a reduced risk of asthma
exacerbations (Williams 2011). Williams and colleagues also re-
ported that the hazard ratio (HR) for an asthma exacerbation is
reduced by 39% in those with more than 75% adherence com-
pared to those with less than 25% adherence (HR 0.61; 95% con-
fidence interval (CI) 0.41 to 0.90). The same study estimated that
24% of exacerbations were attributable to non-adherence to ICS
(Williams 2011).
In those prescribed LABAs, adherence is closely linked to ICS ad-
herence as current guidance suggests that they should not be pre-
scribed separately in asthma, due to safety concerns (BTS/SIGN
2016). Adherence rates to oral medication such as LTRAs, while
better than for ICS, are still sub-optimal (Carter 2003; Sherman
2001). The literature addressing adherence to injectable therapy
is sparse, but most patients are reported to miss doses, especially
when on a more frequent dosing regimen (Janson 2015). Given
the prominence of ICS as the mainstay of maintenance treatment
in asthma, much of the current literature focuses on improving
adherence to ICS (Normansell 2017).
Adherence is defined by the World Health Organization (WHO)
as “the degree to which use of medication by the patient cor-
responds with the prescribed regimen”, and the “diversity and
complexity of adherence behaviour” is recognised (WHO Report
2003). Non-adherence can be understood in terms of intent: “in-
tentional non-adherence” describes an active decision by the pa-
tient not to take the treatment as prescribed, and “unintentional
non-adherence” describes a more passive process in which the pa-
tient does not adhere to treatment due to circumstances not within
their control, for example, a failure to understand the instructions
or remember to take the medication (Gadkari 2012). Reasons for
non-adherence to asthma therapies vary between and within indi-
viduals, over time, and according to how adherence is defined or
measured (Barber 2004). Commonly cited factors associated with
non-adherence include: treatment complexity; cost; administra-
tion route; patient beliefs about asthma or the treatment; lower
socioeconomic status; inclusion in a minority ethnic group and
fewer years of education (Bender 2005; Bårnes 2015; Clark 1999;
Cochrane 1999; Horne 1999; Horne 2002). The difference in on-
set of action between the preventer and reliever medication may
also act as a barrier to adherence; ICS can take two to three weeks
to have an effect (Phillips 2004), rather than providing the im-
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mediate symptom relief experienced with SABA therapies, which
may diminish patient-perceived need for treatment with ICS, and
encourage over-reliance with SABA medication (O’Byrne 2017).
The use of combined ICS and LABA inhalers as both a mainte-
nance and reliever treatment has proven useful, but this does not
address other reasons for poor adherence. The National Review
of Asthma deaths in 2014 confirmed non-adherence to preventer
ICS is associated with increased risk of poor asthma control and
should be continually monitored to prevent deaths due to asthma
(NRAD 2014).
Description of the intervention
As adherence varies within and between individuals it may be best
understood as a behaviour that is drivenby a dynamic combination
of both patient perception and practical factors, rather than as a
stable characteristic that responds to a particular type of interven-
tion over another (Barber 2004; Nunes 2009). By examining past
adherence interventions using an approach that considers non-ad-
herence as a behaviour, health psychology theories and models of
behaviour change can be applied to understand which interven-
tions work and why (Craig 2008; Craig 2013; Glanz 2010;Michie
2008; Stavri 2012). This is in line with current Medical Research
Council (MRC) guidance for the development of complex inter-
ventions, which recommends the use of theory and models of be-
haviour change to evaluate the mechanisms behind interventions
(Craig 2008; Craig 2013).
In the context of improving medication adherence, health psy-
chology interventions target factors that are known to be associ-
ated with medication non-adherence and are deemed to be poten-
tially modifiable to change. Research-evidenced health psychology
theories underpin the development of interventions with planned
assumptions about the outcomes under investigation. Health psy-
chology theory can be used to understand interventions in dif-
ferent ways: to identify the factors that drive a particular health
behaviour which could be targets for an intervention (such as
treatment beliefs); to select behaviour change techniques to ad-
dress the factors influencing the behaviour (such as the use of re-
minders and feedback); or to identify people who are most likely
to benefit from the intervention (Webb 2010). Understanding the
behavioural mechanisms which drive adherence helps to inform
the future design of effective interventions; and finding out why
an intervention does or does not work provides insights into the
characteristics of effective versus less effective interventions (Craig
2008; Craig 2013).
This review aims to determine the effectiveness of theory-based
adherence interventions, and to identify the characteristics of ef-
fective adherence interventions in asthma in terms of the health
psychology theories and behaviour change techniques used in the
intervention. The review will use published coding schemes and
frameworks to identify the theories and techniques used in the
intervention content, namely the Theory Coding Scheme (TCS)
(Michie 2010), and the Theoretical Domain Framework (TDF)
(Michie 2005). The TCS is a research tool which reliably describes
the theoretical basis of interventions and the extent to which the-
ory has been applied, thus allowing assessment of the different
ways that interventions have used theory (Michie 2010). TheTDF
is a synthesis of 33 theories of behaviour and behaviour changes,
grouped into 14 domains, and can be used to: identify influences
on behaviours; design, implement, and evaluate interventions; and
map behaviour change techniques used in interventions (Atkins
2017; Cane 2012).
How the intervention might work
There have been multiple adherence intervention studies con-
ducted in the last decade. Most interventions appear to have lim-
ited effectiveness; and even among those that have demonstrated
an effect, the effect size was small (Nieuwlaat 2014). A possible
reason for the limited effectiveness is that the focus of previous
interventions has been on sociodemographic barriers to adherence
rather than on the behavioural aspects. Despite the large num-
ber of studies, no single sociodemographic factor, or group of fac-
tors, has consistently been shown to be predictive of adherence
(DiMatteo 2004; Jackson 2010; Karamanidou 2008). There is
much overlap between the sociodemographic categories. Further-
more, none of sociodemographic characteristics explain adherence
as a health behaviour that is influenced by patient perceptions
and beliefs. Current National Institute for Health and Care Excel-
lence (NICE) guidelines recommend approaching non-adherence
by focusing on perceptual and practical factors, where perceptual
barriers are differentiated from practical barriers which influence
adherence, as interventions to address these two types of barrier
are likely to involve different techniques (Nunes 2009). There is a
need for intervention content to focus on the perceptual barriers -
understanding how patients interact with their treatment - rather
than just on the individual patient themselves, without explicit
acknowledgement of this complex interaction.
In line with this, several psychological theories - for example, the
health belief model and the self-regulation theory - have been pro-
posed and applied to explain adherence behaviour and to develop
adherence interventions (Holmes 2014). These theories propose
that patient adherence to treatment is driven by an underlying
thought process, which is shaped by various perceptions, beliefs,
and past experiences. It recognises adherence as a behaviour, and
also recognises that behaviours are complex processes which re-
quire complex interventions. Complex interventions usually con-
sist of several behaviour change techniques which influence the
target behaviour. There is an increasing amount of literature sup-
porting the use of theory in intervention development, showing
that interventions which are informed by theory in their devel-
opment are more effective than interventions which lack a the-
oretical basis (Conn 2017; Heath 2015; Holmes 2014; Marteau
2006;McCullough 2016;Michie 2007;Munro 2007; Noar 2007;
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Painter 2008; Webb 2010). However, previous reviews have not
explored the application of theory in adherence interventions in
asthma, nor the extent to which theory has been applied, and what
particular behaviour change techniques have been used. A recent
systematic review evaluated adherence interventions in chronic
respiratory conditions including asthma and the use of behaviour
change theory (McCullough 2016), and it reported that use of
theory was more common amongst effective interventions. How-
ever, it only reported on whether theory was used or not in the
intervention, rather than the extent to which theory was used to
guide the intervention development or how theory was applied
(i.e. through what behaviour change techniques) and how this in-
fluenced intervention effectiveness.
Why it is important to do this review
Most of the existing literature focuses on adherence to ICS. Sub-
optimal adherence leads to poorer clinical outcomes and increased
health service utilisation. Although difficult to quantify, studies
report that up to, and possibly in excess of, 50% of participants are
non-adherent to their prescribed ICS (Bårnes 2015; Bender 2004;
Mahkinova 2015; Murphy 2012; Rand 1994; Williams 2003).
Failure to take appropriate medication was found to be a poten-
tially avoidable factor contributing to approximately one-third of
asthma deaths in the UK over the course of a year (NRAD 2014).
Mahkinova and colleagues demonstrated that patients who are ad-
herent to their preventer medication make fewer claims for oral
corticosteroid prescriptions, reflecting a lower rate of exacerbation
(Mahkinova 2015). An association has also been identified be-
tween hospitalisations and emergency department visits and non-
adherence to ICS (Williams 2003). Murphy and colleagues found
that non-adherence was an independent predictor of the need
for ventilation therapy in acute severe asthma, as well as lower
forced expiratory volume in one second (FEV1) and higher spu-
tum eosinophils, markers of poorly controlled asthma and ongo-
ing inflammation (Murphy 2012). Another study identified an
association between poorer asthma control and lower adherence
rates (Lasmar 2009). A 2015 review of ICS adherence in asthma
found that 24% of exacerbations and 60% of asthma-related hos-
pitalisations could be attributed to poor adherence (Bårnes 2015).
In addition, it is well recognised that uncontrolled asthma places
a greater financial burden on an economy than that of controlled
asthma (Barnes 1996; Global Asthma Report 2014).
This systematic review, which focuses on adherence to ICS only,
builds on a previously publishedCochrane Reviewwhich included
all types of adherence interventions in asthma (Normansell 2017).
The review reported that adherence education, electronic track-
ers or reminders and simplified regimens resulted in better adher-
ence than in control groups. Although the review provided im-
portant information about which intervention type may poten-
tially be more effective than others, it did not examine whether
these differences in effectiveness were due to the incorporation of
health psychology theory in those particular modes of interven-
tion (e.g. adherence education may have been health psychology
theory-based, or may have only focused on education or practical
barriers). This review will give insight into which theories have
been used, how often they have been incorporated in the develop-
ment of adherence interventions, and their potential effectiveness
compared to usual care. We will explore through subgroup anal-
ysis whether theory-based interventions are more or less effective
than interventions that are not theory-based. Further, this review
is being performed as a part of a wider programme of adherence
research in asthma, linked with the Asthma UK Centre for Ap-
plied Research (AUKCAR). The review will provide important
background to the development and design of the adherence in-
terventions used in the future.
O B J E C T I V E S
Main objectives
• To determine the effectiveness of theory-based and non-
theory based health psychology interventions for improving
adherence to maintenance therapy in adults with asthma
Secondary objectives
• To compare the effectiveness of adherence interventions
which are based on theory, as defined by the Theory Coding
Scheme (TCS), to interventions which are not theory-based
• To identify and describe, using the TSC and Theoretical
Domain Framework (TDF), the different health psychology
theories which have been used in interventions to improve
adherence to maintenance therapy in adults with asthma
• To evaluate the extent to which health psychology theory
has been applied to the development of adherence interventions
in asthma
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs). We will in-
clude cluster-randomised trials, providing the data have been or
can be adjusted for clustering. If we identify relevant cross-over
trials we will include only the first period due to the likely carry-
over effects of the intervention. We will include studies reported
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in full text, those published as an abstract only, and unpublished
data.
Types of participants
We will include studies of adults (aged 18 years or more) with a
diagnosis of asthma according to international or national guide-
lines, or as diagnosed by a healthcare professional, and currently
prescribed one or more maintenance asthma therapies. We will
exclude participants with other respiratory comorbidities such as
chronic obstructive pulmonary disease (COPD) or bronchiecta-
sis. We will include studies where only a subset of participants
meet the inclusion criteria, providing disaggregated data can be
obtained.
Types of interventions
We will include studies which examine any intervention with ei-
ther a primary or secondary aim of improving adherence to asthma
maintenance therapy, compared with usual care or a different in-
tervention not specifically aimed at improving adherence.
Wewill include any interventionwhich aims to improve adherence
to asthma maintenance therapy. As one of our secondary aims is
to compare interventions which are based on theory versus those
that are not, we will therefore include both interventions with
theory-based components (either identified explicitly or implied),
and interventions without such components.
We will later classify the interventions used in the studies as ei-
ther: explicit theory (i.e. the authors have defined a priori that
their intervention will be based on a recognised named theory),
implied theory (no particular theory expressed in the methods by
the authors but a clear use of theory can be deduced from the study
description), combined (i.e. theory plus non-theory components),
or no theory components.
Where interventions have not been described in sufficient detail to
determine whether they were based on explicit or implied theory,
or a combination, then we will contact the authors of the studies
to obtain further information. In the case of non-response after
initial contact, study authors will be followed up twice (once every
two weeks). After that, on the grounds that it will not be possible
to accurately classify the study, we will exclude the study from the
subgroup analysis investigating the impact of theory. See Figure 1
for a flow diagram describing the decision process.
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Figure 1. Flow diagram for study selection and inclusion in main subgroup analysis
Interventionsmay be delivered to the participant by any healthcare
professional or trained peer. We will exclude interventions deliv-
ered to a healthcare professional. Interventions may be delivered
face-to-face or virtually, and can be delivered either to individuals
or groups.
Digital adherence interventions, such as short message service
(SMS) interventions or electronic adherence monitors which do
not use health psychology theory will be included in a linked re-
view (Chan 2018, review in development).
Types of outcome measures
The main objective will be evaluated by our primary and sec-
ondary outcomes. The secondary objectives will be evaluated by
subgroup analysis and by using descriptive statistics and narratives
summaries (e.g. percentages, counts and summary tables).
Primary outcomes
1. Adherence to asthma maintenance therapy (as reported by
trialists)
2. Asthma control (measured using a validated tool such as the
Asthma Control Test (Nathan 2004) or Asthma Control
Questionnaire (Juniper 1993), or other validated instrument)
3. Exacerbations requiring at least oral corticosteroid
treatment
We have chosen primary outcomes to reflect those important to
patients, practitioners and policy makers, and in keeping with the
published literature (Reddel 2009).
Secondary outcomes
1. Unscheduled visits to a healthcare provider (primary care
visits, emergency department visits and hospitalisations will be
analysed separately where possible)
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2. Days absent from work
3. Quality of life (measured using a validated tool such as the
Asthma Quality of Life Questionnaire (Juniper 1993), or as
reported by trialists)
4. Adverse events
5. Rescue medication use (e.g. change in puffs per day of
short-acting beta-agonist (SABA), or change in SABA
prescription frequency).
6. Narrative summary of reported cost-effectiveness
Reporting one or more of the outcomes listed here in the study is
not an inclusion criterion for the review.
We will extract data at all reported time points and subgroup out-
comes by the following time points for meta-analysis: < 3 months,
≥ 3 to < 6 months, ≥ 6 to < 12 months and ≥ 12 months. If
studies report post-intervention follow-up, we will extract this in-
formation and present it narratively. If multiple measures of ad-
herence are used, we will include the most objective measure in
the review.
Search methods for identification of studies
Electronic searches
Wewill identify studies from theCochrane Airways Trials Register,
which is maintained by the Information Specialist for the Group.
The Cochrane Airways Trials Register contains studies identified
from several sources:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL), through the Cochrane Register
of Studies Online (crso.cochrane.org);
2. weekly searches of MEDLINE Ovid SP 1946 to date;
3. weekly searches of Embase Ovid SP 1974 to date;
4. monthly searches of PsycINFO Ovid SP 1967 to date;
5. monthly searches of CINAHL EBSCO (Cumulative Index
to Nursing and Allied Health Literature) 1937 to date;
6. monthly searches of AMED EBSCO (Allied and
Complementary Medicine);
7. handsearches of the proceedings of major respiratory
conferences.
Studies contained in the Trials Register are identified through
search strategies based on the scope of Cochrane Airways. Details
of these strategies, as well as a list of handsearched conference pro-
ceedings, are in Appendix 1. See Appendix 2 for search terms used
to identify studies for this review.
We will search the following trials registries:
1. US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov)
2. WHO International Clinical Trials Registry Platform (
www.who.int/trialsearch)
Wewill search theCochrane Airways Trials Register and additional
sources from inception to present, with no restriction on language
of publication.
Searching other resources
We will check the reference lists of all primary studies and review
articles for additional references.
We will search for errata or retractions from included studies pub-
lished in full text on PubMed and report the date this was done
within the review.
Data collection and analysis
Selection of studies
Using the Rayyan application (an online reference screening tool;
Elmagarmid 2014), four review authors (RN, AC, KK, CK) will
screen the titles and abstracts of the search results independently
and code them as ’retrieve’ (eligible or potentially eligible/unclear)
or ’do not retrieve’.We will retrieve the full-text study reports of all
potentially eligible studies and two review authors (RN, AC) will
independently screen them for inclusion, recording the reasons for
exclusion of ineligible studies. We will resolve any disagreement
through discussion or, if required, we will consult a third per-
son/review author (RH). We will identify and exclude duplicates
and collate multiple reports of the same study so that each study,
rather than each report, is the unit of interest in the review. We
will record the selection process in sufficient detail to complete a
PRISMA flow diagram and ’Characteristics of excluded studies’
table (Moher 2009).
Data extraction and management
We will use a data collection form for study characteristics and
outcome data, which has been piloted on at least one study the
meeting inclusion criteria. Four review authors (RN, AC, KK,
CK) will extract the following study characteristics from included
studies.
1. Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and location, study
setting, withdrawals and date of study.
2. Participants: number, mean age, age range, gender,
socioeconomic data (e.g. income, education levels, deprivation
index etc., where available) severity of condition, diagnostic
criteria, baseline lung function, smoking history, inclusion
criteria and exclusion criteria.
3. Interventions: intervention target (primary and secondary),
implementer, type of health psychology theory used*, explicitly
stated theory versus no explicit theory stated, complex (i.e.
comprising several interacting components (Campbell 2000)) or
non-complex, comparison, concomitant medications and
excluded medications. We will use the Theory Coding Scheme
(TCS) and Theoretical Domain Framework (TDF)* to record
the way in which each study has applied theory to their
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intervention. We will use the TIDIER checklist to report
intervention components (Hoffmann 2014).
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for studies and notable conflicts of interest
of trial authors.
Four review authors (RN, AC, KK, CK) will undertake duplicate
data extraction from included studies. We will note in the ’Char-
acteristics of included studies’ table if outcome data were not re-
ported in a usable way.Wewill resolve disagreements by consensus
or by involving a third person/review author (RH). Two review
authors (RN, AC) will transfer data into the Review Manager file
(RevMan 2014). We will double-check that data are entered cor-
rectly by comparing the data presented in the systematic review
with the study reports.
*The TCS can be used to code how theory has been used in
the design of the adherence intervention. These items can iden-
tify whether theory was used to select recipients of the interven-
tion, and to design and tailor the intervention. The items can be
summed to provide a ’use of theory’ score - previous literature has
based this score on items 1 to 11 as these relate to the intervention
design - which can help quantify the extent that theory was used in
an intervention. Item 5 of the coding scheme highlights whether
theory was used to develop the intervention techniques. Previous
literature has coded interventions as having a ’theoretical basis’ if
this item 5 was checked. Two reviewers can apply the TCS inde-
pendently; discrepancies can be resolved by consensus discussion
with a third independent author (Webb 2010). We will use the 14
domains of the TDF to further explore and describe intervention
components.
Assessment of risk of bias in included studies
Two review authors (AC, KK) will assess risk of bias indepen-
dently for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will resolve any disagreements by discussion or by involving
another author (RN). We will assess the risk of bias according to
the following domains:
1. random sequence generation;
2. allocation concealment;
3. blinding of participants and personnel;
4. blinding of outcome assessment;
5. incomplete outcome data;
6. selective outcome reporting;
7. other bias.
We will judge each potential source of bias as high, low or un-
clear and provide a quote from the study report together with a
justification for our judgement in the ’Risk of bias’ table. We will
summarise the ’Risk of bias’ judgements across different studies for
each of the domains listed.Wewill consider blinding separately for
different key outcomes where necessary (e.g. for unblinded out-
come assessment, risk of bias for all-cause mortality may be very
different than for a patient-reported pain scale). Where informa-
tion on risk of bias relates to unpublished data or correspondence
with a trialist, we will note this in the ’Risk of bias’ table.
When considering treatment effects, we will take into account the
risk of bias for the studies that contribute to that outcome.
Assessment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and justify any deviations from it in the ’Differences between
protocol and review’ section of the systematic review.
Measures of treatment effect
We will analyse dichotomous data as odds ratios (ORs) and con-
tinuous data as the mean difference (MD) or standardised mean
difference (SMD). If data from rating scales are combined in a
meta-analysis, we will ensure they are entered with a consistent
direction of effect (e.g. lower scores always indicate improvement).
Wewill undertakemeta-analyses only where this is meaningful; we
will only combine studies in which the participants, interventions,
comparator and outcomes are similar enough for a pooled effect
estimate to make sense.
We will describe skewed data narratively (for example, as medians
and interquartile ranges for each group).
Where multiple trial arms are reported in a single study, we will
include only the relevant arms. If two comparisons (e.g. interven-
tion A versus usual care and intervention B versus usual care) are
combined in the same meta-analysis, we will either combine the
active arms or halve the control group to avoid double-counting.
If adjusted analyses are available (ANOVA or ANCOVA) we will
use these as a preference in ourmeta-analyses. If both change-from-
baseline and endpoint scores are available for continuous data,
we will use change-from-baseline unless there is low correlation
between measurements in individuals. If a study reports outcomes
at multiple time points, we will use the latest reported time point.
We will use intention-to-treat (ITT) or ’full analysis set’ analyses
where they are reported (i.e. those where data have been imputed
for participants whowere randomly assigned but did not complete
the study) instead of completer or per protocol analyses.
Unit of analysis issues
For dichotomous outcomes, we will use participants, rather than
events, as the unit of analysis (i.e. number of participants admitted
to hospital, rather than number of admissions per participant).
However, if rate ratios are reported in a study, we will analyse them
on this basis.We plan to include relevant cluster-randomised trials,
but will only include data from such trials in the meta-analyses
if the available data have been adjusted (or can be adjusted), to
account for the clustering. Based on recommendations from the
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Cochrane Handbook, we will adjust cluster-randomised data by
inflating standard errors using a design effect (DE) calculated with
an intracluster correlation coefficient (ICC).
Dealing with missing data
We will contact investigators or study sponsors in order to verify
key study characteristics and obtain missing numerical outcome
data where possible (e.g. when a study is identified as an abstract
only). Where this is not possible, and the missing data are thought
to introduce serious bias, we will take this into consideration in
the GRADE rating for affected outcomes.
Assessment of heterogeneity
We will use the I² statistic to measure heterogeneity among the
studies in each analysis. If we identify substantial heterogeneity
we will report it and explore the possible causes by prespecified
subgroup analysis. Furthermore, to aid interpretationof the pooled
estimates, we will construct a summary table outlining the key
features of the included studies to allow easy comparison between
trials contributing data to the review. We will explore possible
clinical heterogeneity narratively in the discussion.
Assessment of reporting biases
If we are able to pool more than 10 studies, we will create and
examine a funnel plot to explore possible small-study and publi-
cation biases.
Data synthesis
We will use a random-effects model and perform a sensitivity
analysis with a fixed-effect model.
’Summary of findings’ table
We will create a ’Summary of findings’ table using the following
outcomes at longest follow up point: adherence to asthma main-
tenance therapy; asthma control; exacerbations requiring at least
oral corticosteroid treatment; unscheduled visits to a healthcare
provider; days absent fromwork; quality of life; and adverse events.
We will use the five GRADE considerations (risk of bias, consis-
tency of effect, imprecision, indirectness and publication bias) to
assess the quality of the body of evidence as it relates to the studies
that contribute data for the prespecified outcomes. We will use
the methods and recommendations described in Section 8.5 and
Chapter 12 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011), using GRADEpro GDT software
(GRADEproGDT).We will use footnotes to document our justi-
fication of all decisions to downgrade our assessments of the qual-
ity of evidence, and we will make comments to aid the reader’s
understanding of the review where necessary.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses.
1. Inteventions which specify the use of theory explicitly to
design their intervention (score of “yes” at item 5 of TCS) versus
implied theory (score of “no” at item 5 of TSC, but theory use
implied) versus those interventions with no evidence of use of
theory
2. Interventions using only theory versus those using both
theory and non-theory components
3. Interventions using theory throughout entire intervention
versus those using theory for one component of the intervention
4. Type of adherence measure used (e.g. subjective versus
objective measures)
5. Type of asthma maintenance therapy targeted by adherence
intervention (inhaled/nebulised versus oral versus injectable)
6. Baseline treatment of participants (inhaled corticosteroids
(ICS) alone versus ICS/long-acting beta2-agonists in a
combination inhaler)
7. Method of randomisation (cluster versus patient level)
We will use the following outcomes in subgroup analyses.
1. Adherence to asthma maintenance therapy
2. Asthma control
3. Exacerbations requiring at least oral corticosteroid
treatment
We will use the formal test for subgroup interactions in Review
Manager 5 (RevMan 2014).
Sensitivity analysis
We plan to carry out the following sensitivity analyses, for the
primary outcomes.
1. Exclusion of unpublished data
2. Exclusion of trials with high risk of selection bias
3. Exclusion of trials with mixed participant samples (e.g.
where asthma patient data were extracted from a trial with
asthma and COPD patients)
4. Run the main analysis with more and less conservative
estimates of the ICC (to assess the impact of cluster-
randomisation)
We will compare the results from a fixed-effect model with those
using a random-effects model.
A C K N OW L E D G E M E N T S
The Background and Methods sections of this protocol are based
on a standard template used by Cochrane Airways and on a pre-
viously published related Cochrane Review (Normansell 2017).
Professor Rob Horne was involved in providing expert advice in
his role as Professor of Behavioural Medicine, UCL, on the back-
ground, rationale and methods sections of early protocol drafts.
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Amanda McCullough was the editor for this protocol and com-
mented critically on it.
This project was supported by the National Institute for Health
Research, via Cochrane Infrastructure funding to Cochrane Air-
ways. The views and opinions expressed therein are those of the
authors and do not necessarily reflect those of the Systematic Re-
views Programme, NIHR, NHS or the Department of Health.
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A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Trials Register
Electronic searches: core databases
Database Frequency of search
CENTRAL (the Cochrane Library) Monthly
MEDLINE (Ovid) Weekly
Embase (Ovid) Weekly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify studies from the Cochrane Airways Trials Register
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Asthma search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti-asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify studies in other electronic databases.
Appendix 2. Search strategy to identify relevant studies from the Cochrane Airways Trials Register
(via Cochrane Register of Studies (CRS))
Search line Search terms Notes
#1 AST:MISC1 MISC1 is field in the record where the reference has been
coded for condition, in this case, asthma
#2 MeSH DESCRIPTOR Asthma Explode All Index term has been exploded to include all narrow terms
to asthma
#3 asthma*:ti,ab Text word search in title & abstract fields
#4 #1 or #2 or #3 Combines all population terms
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(Continued)
#5 MESH DESCRIPTOR Treatment Adherence and Com-
pliance EXPLODE ALL
Index termhas been exploded to include all narrower terms
#6 adhere* or nonadhere* or non-adhere*:ti,ab,kw text word search in title, abstract & keyword fields
#7 complian* or noncomplian* or non-complian*:ti,ab,kw text word search in title, abstract & keyword fields
#8 refusal or refuse*:ti,ab,kw text word search in title, abstract & keyword fields
#9 concord*:ti,ab,kw text word search in title, abstract & keyword fields
#10 conform*:ti,ab,kw text word search in title, abstract & keyword fields
#11 accept*:ti,ab,kw text word search in title, abstract & keyword fields
#12 comply*:ti,ab,kw text word search in title, abstract & keyword fields
#13 {OR #5-#12} Combines all adherence terms
#14 #4 AND #13 Combines the population and adherence terms
C O N T R I B U T I O N S O F A U T H O R S
Rebecca Normansell: draft protocol, develop search strategy, obtain full-text reports, carry out and interpret analyses, draft final review.
Amy Chan: draft protocol, screen search, obtain full-text reports, carry out and interpret analyses, draft final review
Caroline Katzer: draft protocol, screen search, obtain full-text reports, interpret analyses, draft final review.
Kayleigh M Kew: draft protocol, interpret analyses, draft final review.
Marissa Mes: draft protocol, obtain full-text reports, interpret analysis, draft final review.
Chris J Newby: draft protocol, carry out and interpret analyses, draft final review.
Anoop Chauhan: draft protocol, draft final review.
Stephanie JC Taylor: draft protocol, develop search strategy, interpret analyses, draft final review.
Hilary Pinnock: draft protocol, draft final review.
Aziz Sheikh: draft protocol, draft final review.
Vari Wileman: draft protocol, interpret analyses, draft final review.
16Health psychology interventions to improve adherence to maintenance therapies in asthma (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D E C L A R A T I O N S O F I N T E R E S T
Rebecca Normansell: I am Joint Co-ordinating Editor of Cochrane Airways, employed by an NIHR grant, and a qualified general
practitioner.
Amy Chan: I have received consultancy fees from Janssen-Cilag, speaker fees from Novartis, and travel grants from Maurice Phyllis
Paykel Trust and Max Health for activities outside this submitted work. I am also a freelance consultant for Spoonful of Sugar Limited,
a University College London spin-out behaviour change consultancy company.
Caroline Katzer: I am funded by the NIHR Collaboration for Leadership in Applied Health Research and Care North Thames. I
am also a freelance consultant for Spoonful of Sugar Limited, a University College London spin-out behaviour change consultancy
company.
Kayleigh M Kew: I was a paid researcher on a National Institute for Health Research (NIHR) Cochrane Programme Grant until
December 2016. The grant was awarded to the Cochrane Airways review group at St George’s, University of London, where I continued
as an honorary research assistant until April 2017. Part of the work underpinning this review was undertaken during the course of the
grant.
Marissa A Mes: I am completing a PhD that is fully funded by the National Institute of Health Research Collaboration for Leadership
in Applied Health Research and Care (NIHR CLAHRC) North Thames. My PhD is based at the University College London School
of Pharmacy, and is affiliated with the Asthma UK Centre for Applied Research (AUKCAR). I have completed freelance work for
Spoonful of Sugar Limited, a University College London spin-out behaviour change consultancy company
Chris J Newby: I am a co-applicant on a NIHR programme grant.
Anoop Chauhan: I have a clinical and academic interest in severe asthma, and have been Chief Investigator on many asthma trials
evaluating new technologies and treatment effects. Adherence measurements are an important part of this work. I have also received
research grants, consultancy fees and honoraria for educational meetings from Novartis, Boehringer Ingelheim, Pfizer, TEVA, Astra
Zeneca and Airsonett.
Stephanie JC Taylor: I have no known conflicts of interest.
Hilary Pinnock: I have an academic interest in self-management of asthma (including adherence); I chair the Evidence Review Group
on Self-management (including adherence) for the BTS/SIGN British Asthma Guideline. My university receives funding from Asthma
UK for the Asthma UK Centre for Applied Research, and had a recent grant from the NIHR Programme Grants for Applied Research
investigating implementation of asthma self-management. I regularly speak on the subject of asthma self-management (including
adherence) at educational meetings, sometimes receiving an honorarium. Boehringer Ingelheim (who do not have a specific interest in
self-management or adherence) paid for my accommodation in London for the ERS 2016.
Aziz Sheikh: I am Director of the Asthma UK Centre for Applied Research.
Vari Wileman: I am employed by the North London NIHR CLAHRC.
S O U R C E S O F S U P P O R T
Internal sources
• The authors declare that no such funding was received for this systematic review, Other.
17Health psychology interventions to improve adherence to maintenance therapies in asthma (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
External sources
• The authors declare that no such funding was received for this systematic review, Other.
18Health psychology interventions to improve adherence to maintenance therapies in asthma (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
